ClinicalTrials.gg
CompletedNCT01338896Updated Aug 30, 2011

Study to Compare Adhesiveness of Two Different Rotigotine Patch Formulations

A Phase 1 interventional study of Rotigotine transdermal patch in Parkinson's Disease, sponsored by UCB Pharma. Completed at 16 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-08-30.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 44 studies testing rotigotine in Parkinson Disease — 1 open to participants now, 1 under way, none of them phase 3. rotigotine · Parkinson Disease.

Enrollment
32nd of 42
56 · median 123
Started
2011
with 1 other
Phase 1
6 of 44
none open now
Registered
20th of 44
by date
Lead sponsor
22 of 44
UCB Pharma

Among the 44 studies testing rotigotine in Parkinson Disease, this one is the 32nd largest by enrollment of the 42 interventional ones that give a count, is one of 2 that started in 2011, is one of 6 in phase 1, and was the 20th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 44 studies testing rotigotine in Parkinson Disease is open now. Recruiting first, the newest first:

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing rotigotine in Parkinson Disease, or all of them as a file.
02

Study summary

The primary objective of the study is to compare the adhesiveness of two different patch formulations of rotigotine using patch size 40 cm2, under the assumption that both patch formulations show similar adhesiveness properties.

03

Conditions studied

  • Parkinson's Disease

Browse trials for

Keywords

  • Rotigotine
  • Neupro
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects with a diagnosis of idiopathic Parkinson´s disease, and continuous treatment with commercially available rotigotine transdermal patch for at least 3 months, and a stable rotigotine dose including an 8 mg/24 h patch for at least 2 weeks prior to enrollment

Exclusion criteria

Exclusion Criteria:

  • Subjects has previously participated in this study, failed to be screened, or has participated in another study with an medicinal product (IMP) or medical device within the last 30 days or is currently participating in such
  • Subject with a history of significant skin to adhesives, other transdermal products or recently unsolved contact dermatitis
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Sequence A-B

    4 day treatment (Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1 followed by Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1)

    Drug: Rotigotine transdermal patch

  • Experimental
    Sequence B-A

    4 day treatment (Treatment B: Rotigotine transdermal patch 8 mg/24 h reference patch PR 2.1.1 followed by Treatment A: Rotigotine transdermal patch 8 mg/24 h, test product PR 2.2.1)

    Drug: Rotigotine transdermal patch

Interventions

06

What researchers measure

Primary outcomes

  1. The average adhesiveness score of 2 days of 24 hours patch application as rated by the investigator (or designee)

    The international patch adhesiveness score

    Time frame: 2 days of 24 hours patch application

Secondary outcomes

  1. Patch adhesiveness of first treatment day as rated by the investigator (or designee) 24 hours after patch application

    The international patch adhesiveness score

    Time frame: after 24 hours of patch application

  2. Patch adhesiveness of second treatment day as rated by the investigator (or designee) 24 hours after patch application

    The international patch adhesiveness score

    Time frame: after 24 hour of patch application

07

Study locations

16 sites
  • Innsbruck, Austria
  • Wien, Austria
  • Alzenau, Germany
  • Berlin, Germany
  • Boblingen, Germany
  • Bochum, Germany
  • Gera, Germany
  • Karlstadt, Germany
  • Koln, Germany
  • Stuttgart, Germany
  • Wolfach, Germany
  • Blackpool, United Kingdom
  • Derby, United Kingdom
  • Liverpool, United Kingdom
  • Newcastle Upon Tyne, United Kingdom
  • Norwich, United Kingdom
08

References and documents

Publications

  • Elshoff JP, Timmermann L, Schmid M, Arth C, Komenda M, Brunnert M, Bauer L. Comparison of the bioavailability and adhesiveness of different rotigotine transdermal patch formulations. Curr Med Res Opin. 2013 Dec;29(12):1657-62. doi: 10.1185/03007995.2013.841666. Epub 2013 Sep 23. PubMed 24006953 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2011, a primary completion of May 2011 and a completion of Jun 2011. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2011
First posted
Apr 20, 2011
Start
Apr 2011
Primary completionActual
May 2011
CompletionActual
Jun 2011
Last update
Aug 30, 2011
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 30, 2011, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01338896
Lead sponsor
UCB Pharma
Responsible party
Sponsor
First posted
Apr 20, 2011
Start date
Apr 2011
Primary completion
May 2011
Completion
Jun 2011
Last update
Aug 30, 2011

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2011. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion